Are you Dr. Abella?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 34 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1432 S Dobson Rd
Ste 107
Mesa, AZ 85202Phone+1 480-833-1123Fax+1 480-833-1124- Is this information wrong?
Summary
- Dr. Esteban Abella, MD is a pediatric hematologist/oncologist in Mesa, Arizona. He is currently licensed to practice medicine in Arizona.
Education & Training
- Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 1988 - 1991
- Universidad Central del Este Facultad de MedicinaClass of 1985
Certifications & Licensure
- AZ State Medical License 2003 - 2025
Clinical Trials
- Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Start of enrollment: 1987 Aug 01
- Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Start of enrollment: 1998 Aug 01
Publications & Presentations
PubMed
- 65 citationsIdelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapyAjay K. Gopal, Brad S. Kahl, Christopher R. Flowers, Peter Martin, Stephen M. Ansell, Esteban Abella-Dominicis, Brian D. Koh, Wei Ye, Paul M. Barr, Gilles Salles, Jona...> ;Blood. 2017 Jun 1
- 116 citationsPhase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHLPaul M. Barr, Gene Brian Saylors, Stephen E. Spurgeon, Bruce D. Cheson, Daniel Reif Greenwald, Susan O'Brien, Andre K. D. Liem, Rosemary E. Mclntyre, Adarsh Joshi, Est...> ;Blood. 2016 May 19
- 18 citationsAssessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Gary H. Lyman, David C. Dale, Jason C. Legg, Esteban Abella, Phuong Khanh Morrow, Sadie Whittaker, Jeffrey Crawford> ;Cancer Medicine. 2015 Aug 1
- Join now to see all
Press Mentions
- Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)June 3rd, 2019